Bg pattern

METALYSE 10,000 UNITS (50 MG) POWDER AND SOLVENT FOR INJECTABLE SOLUTION

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use METALYSE 10,000 UNITS (50 MG) POWDER AND SOLVENT FOR INJECTABLE SOLUTION

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Introduction

Package Leaflet: Information for the User

Metalyse 8,000 units (40 mg) powder and solvent for solution for injection

Metalyse 10,000 units (50 mg) powder and solvent for solution for injection

tenecteplase

Read all of this leaflet carefully before you are given this medicine because it contains important information for you.

  • Keep this leaflet, you may need to read it again.
  • If you have any further questions, ask your doctor or pharmacist.
  • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the pack

  1. What Metalyse is and what it is used for
  2. What you need to know before you are given Metalyse
  3. How Metalyse is given
  4. Possible side effects
  5. Storage of Metalyse
  6. Contents of the pack and other information

1. What Metalyse is and what it is used for

Metalyse is a powder and solvent for solution for injection.

Metalyse belongs to a group of medicines called thrombolytics. These medicines help to dissolve blood clots. Tenecteplase is a recombinant fibrin-specific plasminogen activator.

Metalyse is used to treat heart attacks (myocardial infarctions) within 6 hours of the start of symptoms and helps to dissolve blood clots that have formed in the heart's blood vessels. This helps to prevent damage caused by heart attacks and has been shown to save lives.

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before you are given Metalyse

Metalyse will not be prescribed or given to you by your doctor

  • if you have previously had a severe allergic reaction (hypersensitivity) to tenecteplasa, to any of the other ingredients of this medicine (listed in section 6) or to gentamicin (a residual substance from the manufacturing process). If treatment with Metalyse is still considered necessary, resuscitation equipment must be available for immediate use if needed;
  • if you have, or have recently had, a condition that increases your risk of bleeding (haemorrhage), including:
  • a bleeding disorder or tendency to bleed
  • stroke (cerebrovascular accident)
  • very high blood pressure, not controlled
  • a recent head injury
  • severe liver disease
  • a stomach ulcer (peptic ulcer)
  • varices (enlarged veins) in the gullet (oesophageal varices)
  • blood vessel abnormalities (e.g. an aneurysm)
  • certain tumours
  • inflammation of the sac surrounding the heart (pericarditis); inflammation or infection of the heart valves (endocarditis)
  • dementia;
  • if you are taking medicines to "thin" the blood, such as warfarin (anticoagulants);
  • if you have an inflamed pancreas (pancreatitis);
  • if you have recently had major surgery, including brain or spinal surgery;
  • if you have had cardiopulmonary resuscitation (chest compressions) for more than 2 minutes in the last 2 weeks.

Warnings and precautions

Your doctor will be careful when giving you Metalyse

  • if you have had any allergic reaction other than a severe allergic reaction (hypersensitivity) to tenecteplasa, to any of the other ingredients of this medicine (listed in section 6) or to gentamicin (a residual substance from the manufacturing process);
  • if you have high blood pressure;
  • if you have problems with blood circulation in the brain (cerebrovascular disease);
  • if you have had bleeding in the gut or urinary tract in the last 10 days (this could cause blood in your stools or urine);
  • if you have a heart valve abnormality (e.g. mitral stenosis) with an irregular heartbeat (e.g. atrial fibrillation);
  • if you have had an intramuscular injection in the last 2 days;
  • if you are over 75 years old;
  • if you weigh less than 60 kg;
  • if you have been given Metalyse before.

Children and adolescents

Metalyse is not recommended for use in children and adolescents under 18 years.

Other medicines and Metalyse

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

Pregnancy and breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before being given this medicine.

3. How Metalyse is given

Your doctor will calculate your dose of Metalyse based on your body weight, according to the following scheme:

Body weight (kg)

Less than 60

60 to 70

70 to 80

80 to 90

More than 90

Metalyse (U)

6,000

7,000

8,000

9,000

10,000

Your doctor will give you a medicine to prevent blood clotting, as well as Metalyse, as soon as possible after your chest pain starts.

Metalyse is given as a single injection into a vein by a doctor with experience in the use of this type of medicine.

Your doctor will give you Metalyse as soon as possible after the start of your chest pain, as a single dose.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

The following side effects have been experienced by patients given Metalyse:

Very common (may affect more than 1 in 10 people):

  • bleeding

Common (may affect up to 1 in 10 people):

  • bleeding at the injection or puncture site
  • nosebleeds
  • genitourinary bleeding (you may see blood in your urine)
  • bruising
  • gastrointestinal bleeding (e.g. bleeding from the stomach or intestines)

Uncommon (may affect up to 1 in 100 people):

  • irregular heartbeats (reperfusion arrhythmias), which can occasionally lead to cardiac arrest. Cardiac arrest can be life-threatening.
  • internal bleeding in the abdomen (retroperitoneal bleeding)
  • bleeding in the brain (cerebral bleeding). After a brain bleed or other serious bleeding events, death or permanent disability can occur.
  • bleeding in the eyes (ocular bleeding)

Frequency not known (cannot be estimated from the available data):

  • low blood pressure (hypotension)
  • bleeding in the lungs (pulmonary bleeding)
  • allergic reactions (anaphylactoid reactions), e.g. rash, hives, difficulty breathing (bronchospasm)
  • bleeding in the area surrounding the heart (haemopericardium)
  • blood clots in the lungs (pulmonary embolism) and in the blood vessels of other organ systems (thrombotic embolisms)

Frequency not known (cannot be estimated from the available data):

  • fat embolism (clots formed by fat)
  • nausea
  • vomiting
  • increased body temperature (fever)
  • blood transfusions as a result of bleeding

As with other thrombolytic agents, the following events have been described as a consequence of myocardial infarction and/or thrombolytic administration:

Very common (may affect more than 1 in 10 people):

  • low blood pressure (hypotension)
  • irregular heartbeats
  • chest pain (angina)

Common (may affect up to 1 in 10 people):

  • additional chest pain/angina (recurrent ischaemia)
  • heart attack
  • heart failure
  • shock due to heart failure
  • inflammation of the heart lining
  • fluid in the lungs (pulmonary oedema)

Uncommon (may affect up to 1 in 100 people):

  • cardiac arrest
  • problems with the heart valves or heart lining (mitral regurgitation, pericardial effusion)
  • blood clots in the veins (venous thrombosis)
  • fluid between the heart lining and the heart (cardiac tamponade)
  • tear in the heart muscle (myocardial rupture)

Rare (may affect up to 1 in 1,000 people):

  • blood clots in the lungs (pulmonary embolism)

These cardiovascular events can be life-threatening and may lead to death.

In the case of brain bleeding, effects related to the nervous system have been described, e.g. drowsiness, speech disorders, paralysis of parts of the body (hemiparesis) and convulsions.

Reporting of side effects

If you experience any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Metalyse

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the label and carton after EXP.

Do not store above 30°C.

Store the pack in the outer carton to protect from light.

After reconstitution, Metalyse can be stored for 24 hours at 2-8°C and 8 hours at 30°C. However, for microbiological reasons, your doctor will normally use the reconstituted injection solution immediately.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.

6. Contents of the pack and other information

What Metalyse contains

  • The active substance is tenecteplase.
  • Each vial contains 8,000 units (40 mg) of tenecteplase. Each pre-filled syringe contains 8 ml of solvent. Each ml contains 1,000 units of tenecteplase when reconstituted with 8 ml of solvent.

or

  • Each vial contains 10,000 units (50 mg) of tenecteplase. Each pre-filled syringe contains 10 ml of solvent. Each ml contains 1,000 units of tenecteplase when reconstituted with 10 ml of solvent.
  • The other ingredients are arginine, phosphoric acid, and polysorbate 20.
  • The solvent is water for injections.
  • It contains gentamicin as a residual substance from the manufacturing process.

Appearance and pack contents

The pack contains:

  • a vial with 40 mg of tenecteplase as a lyophilised powder, a pre-filled syringe with 8 ml of solvent, and a vial adapter.

or

  • a vial with 50 mg of tenecteplase as a lyophilised powder, a pre-filled syringe with 10 ml of solvent, and a vial adapter.

Marketing authorisation holder and manufacturer

Marketing authorisation holder

Boehringer Ingelheim International GmbH

Binger Strasse 173

55216 Ingelheim am Rhein

Germany

Manufacturer

Boehringer Ingelheim Pharma GmbH & Co. KG

Birkendorfer Strasse 65

88397 Biberach/Riss

Germany

Boehringer Ingelheim France

100-104 avenue de France

75013 Paris

France

You can get more information about this medicine by contacting the representative of the marketing authorisation holder:

België/Belgique/Belgien

Lietuva

Boehringer Ingelheim SComm

Boehringer Ingelheim RCV GmbH & Co KG

Tél/Tel: +32 2 773 33 11

Lietuvos filialas

Tel: +370 5 2595942

България

Luxembourg/Luxemburg

Boehringer Ingelheim Bulgaria EOOD

Boehringer Ingelheim SComm

Tél/Tel: +32 2 773 33 11

Tel: +359 2 958 79 98

Ceská republika

Magyarország

Boehringer Ingelheim spol. s r.o.

Boehringer Ingelheim RCV GmbH & Co KG

Magyarországi Fióktelepe

Tel: +420 234 655 111

Tel: +36 1 299 89 00

Danmark

Malta

Boehringer Ingelheim Danmark A/S

Boehringer Ingelheim Ireland Ltd.

Tlf: +45 39 15 88 88

Tel: +353 1 295 9620

Deutschland

Nederland

Boehringer Ingelheim Pharma GmbH & Co. KG

Boehringer Ingelheim B.V.

Tel: +49 (0) 800 77 90 900

Tel: +31 (0) 800 22 55 889

Eesti

Norge

Boehringer Ingelheim RCV GmbH & Co KG Eesti filiaal

Boehringer Ingelheim Norway KS

Tel: +372 612 8000

Tlf: +47 66 76 13 00

Ελλάδα

Österreich

Boehringer Ingelheim Ελλάς Μονοπρόσωπη Α.Ε.

Boehringer Ingelheim RCV GmbH & Co KG

Tηλ: +30 2 10 89 06 300

Tel: +43 1 80 105-7870

España

Polska

Boehringer Ingelheim España, S.A.

Boehringer Ingelheim Sp. z o.o.

Tel: +34 93 404 51 00

Tel: +48 22 699 0 699

France

Portugal

Boehringer Ingelheim France S.A.S.

Boehringer Ingelheim Portugal, Lda.

Tél: +33 3 26 50 45 33

Tel: +351 21 313 53 00

Hrvatska

România

Boehringer Ingelheim Zagreb d.o.o.

Boehringer Ingelheim RCV GmbH & Co KG

Tel: +385 1 2444 600

Viena - Sucursala Bucuresti

Tel: +40 21 302 28 00

Ireland

Slovenija

Boehringer Ingelheim Ireland Ltd.

Boehringer Ingelheim RCV GmbH & Co KG

Tel: +353 1 295 9620

Podružnica Ljubljana

Tel: +386 1 586 40 00

Ísland

Slovenská republika

Vistor hf.

Boehringer Ingelheim RCV GmbH & Co KG

Sími: +354 535 7000

organizacná zložka

Tel: +421 2 5810 1211

Italia

Suomi/Finland

Boehringer Ingelheim Italia S.p.A.

Boehringer Ingelheim Finland Ky

Tel: +39 02 5355 1

Puh/Tel: +358 10 3102 800

Κύπρος

Sverige

Boehringer Ingelheim Ελλάς Μονοπρόσωπη Α.Ε.

Boehringer Ingelheim AB

Tηλ: +30 2 10 89 06 300

Tel: +46 8 721 21 00

Latvija

United Kingdom (Northern Ireland)

Boehringer Ingelheim RCV GmbH & Co KG

Boehringer Ingelheim Ireland Ltd.

Latvijas filiale

Tel: +353 1 295 9620

Tel: +371 67 240 011

Date of last revision of this leaflet:

Other sources of information

Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu/.

The leaflet can be found in all EU/EEA languages on the European Medicines Agency website.

Online doctors for METALYSE 10,000 UNITS (50 MG) POWDER AND SOLVENT FOR INJECTABLE SOLUTION

Discuss questions about METALYSE 10,000 UNITS (50 MG) POWDER AND SOLVENT FOR INJECTABLE SOLUTION, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

0.0 (0)
Doctor

Hocine Lokchiri

General medicine 21 years exp.

Dr. Hocine Lokchiri is a French consultant with over 20 years of experience in General and Emergency Medicine. He works with adults and children, helping patients with urgent symptoms, infections, sudden health changes and everyday medical concerns that require timely evaluation. His background includes clinical practice in France, Switzerland and the United Arab Emirates, which allows him to navigate different healthcare systems and manage a wide range of conditions with confidence. Patients value his calm, structured approach, clear explanations and evidence-based decision-making.

Online consultations with Dr. Lokchiri are suitable for many situations when someone needs quick medical guidance, reassurance or a clear next step. Common reasons for booking include:

  • fever, chills, fatigue and viral symptoms
  • cough, sore throat, nasal congestion, breathing discomfort
  • bronchitis and mild asthma flare-ups
  • nausea, diarrhoea, abdominal pain, digestive infections
  • rashes, allergic reactions, redness, insect bites
  • muscle or joint pain, mild injuries, sprains
  • headache, dizziness, migraine symptoms
  • stress-related symptoms, sleep disturbances
  • questions about test results and treatment plans
  • management of chronic conditions in stable phases
Many patients reach out when symptoms appear suddenly and cause concern, when a child becomes unwell unexpectedly, when a rash changes or spreads, or when it’s unclear whether an in-person examination is necessary. His emergency medicine background is particularly valuable online, helping patients understand risk levels, identify warning signs and choose safe next steps.

Some situations are not suitable for online care. If a patient has loss of consciousness, severe chest pain, uncontrolled bleeding, seizures, major trauma or symptoms suggesting a stroke or heart attack, he will advise seeking immediate local emergency services. This improves safety and ensures patients receive the right level of care.

Dr. Lokchiri’s professional training includes:

  • Advanced Trauma Life Support (ATLS)
  • Basic and Advanced Cardiac Life Support (BLS/ACLS)
  • Pediatric Advanced Life Support (PALS)
  • Prehospital Trauma Life Support (PHTLS)
  • eFAST and critical care transthoracic echocardiography
  • aviation medicine
He is an active member of several professional organisations, including the French Society of Emergency Medicine (SFMU), the French Association for Emergency Physicians (AMUF) and the Swiss Society of Emergency and Rescue Medicine (SGNOR). In consultations, he works with clarity and precision, helping patients understand their symptoms, possible risks and the safest treatment options.
Camera Book a video appointment
€58
5.0 (140)
Doctor

Yevgen Yakovenko

General surgery 12 years exp.

Dr. Yevgen Yakovenko is a licensed surgeon and general practitioner in Spain and Germany. He specialises in general, paediatric, and oncological surgery, internal medicine, and pain management. He offers online consultations for adults and children, combining surgical precision with therapeutic support. Dr Yakovenko works with patients across different countries and provides care in Ukrainian, Russian, English, and Spanish.

Areas of medical expertise:

  • Acute and chronic pain: headaches, muscle and joint pain, back pain, abdominal pain, postoperative pain. Identifying the cause, selecting treatment, and creating a care plan.
  • Internal medicine: heart, lungs, gastrointestinal tract, urinary system. Management of chronic conditions, symptom control, second opinions.
  • Pre- and postoperative care: risk assessment, decision-making support, follow-up after surgery, rehabilitation strategies.
  • General and paediatric surgery: hernias, appendicitis, congenital conditions, both planned and urgent surgeries.
  • Injuries and trauma: bruises, fractures, sprains, soft tissue damage, wound care, dressing, referral when in-person care is required.
  • Oncological surgery: diagnosis review, treatment planning, and long-term follow-up.
  • Obesity treatment and weight management: a medical approach to weight loss, including assessment of underlying causes, evaluation of comorbidities, development of a personalised plan (nutrition, physical activity, pharmacotherapy if needed), and ongoing progress monitoring.
  • Imaging interpretation: analysis of ultrasound, CT, MRI, and X-ray results, surgical planning based on imaging data.
  • Second opinions and medical navigation: clarifying diagnoses, reviewing current treatment plans, helping patients choose the best course of action.

Experience and qualifications:

  • 12+ years of clinical experience in university hospitals in Germany and Spain.
  • International education: Ukraine – Germany – Spain.
  • Member of the German Society of Surgeons (BDC).
  • Certified in radiological diagnostics and robotic surgery.
  • Active participant in international medical conferences and research.

Dr Yakovenko explains complex topics in a clear, accessible way. He works collaboratively with patients to analyse health issues and make evidence-based decisions. His approach is grounded in clinical excellence, scientific accuracy, and respect for each individual.

If you are unsure about a diagnosis, preparing for surgery, or want to discuss your test results – Dr Yakovenko will help you evaluate your options and move forward with confidence.

Camera Book a video appointment
€50
5.0 (29)
Doctor

Anna Biriukova

General medicine 6 years exp.

Dr Anna Biriukova is an internal medicine doctor with clinical experience in cardiology, endocrinology, and gastroenterology. She provides online consultations for adults, offering expert medical support for heart health, hormonal balance, digestive issues, and general internal medicine.

Cardiology – Diagnosis and treatment of:

  • High blood pressure, blood pressure fluctuations, and cardiovascular risk prevention.
  • Chest pain, shortness of breath, arrhythmias (tachycardia, bradycardia, palpitations).
  • Leg swelling, chronic fatigue, reduced exercise tolerance.
  • EKG interpretation, lipid profile evaluation, cardiovascular risk assessment (heart attack, stroke).
  • Post-COVID-19 cardiac monitoring and care.
Endocrinology – Diabetes, thyroid, metabolism:
  • Diagnosis and management of type 1 and type 2 diabetes, and prediabetes.
  • Individual treatment plans including oral medications and insulin therapy.
  • GLP-1 therapy– modern pharmacological treatment for weight management and diabetes control, including drug selection, monitoring, and safety follow-up.
  • Thyroid disorders – hypothyroidism, hyperthyroidism, autoimmune thyroid diseases (Hashimoto’s, Graves’ disease).
  • Metabolic syndrome – obesity, lipid disorders, insulin resistance.
Gastroenterology – Digestive health:
  • Abdominal pain, nausea, heartburn, gastroesophageal reflux (GERD).
  • Stomach and intestinal conditions: gastritis, irritable bowel syndrome (IBS), indigestion.
  • Management of chronic digestive disorders and interpretation of tests (endoscopy, ultrasound, labs).
General internal medicine and preventive care:
  • Respiratory infections – cough, colds, bronchitis.
  • Lab test analysis, therapy adjustments, medication management.
  • Adult vaccinations – planning, contraindications assessment.
  • Cancer prevention – screening strategies and risk assessment.
  • Holistic approach – symptom relief, complication prevention, and quality of life improvement.
Dr Biriukova combines internal medicine with specialist insight, offering clear explanations, personalised treatment plans, and comprehensive care tailored to each patient.
Camera Book a video appointment
€60

Frequently Asked Questions

Is a prescription required for METALYSE 10,000 UNITS (50 MG) POWDER AND SOLVENT FOR INJECTABLE SOLUTION?
METALYSE 10,000 UNITS (50 MG) POWDER AND SOLVENT FOR INJECTABLE SOLUTION requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
What is the active substance in METALYSE 10,000 UNITS (50 MG) POWDER AND SOLVENT FOR INJECTABLE SOLUTION?
The active ingredient in METALYSE 10,000 UNITS (50 MG) POWDER AND SOLVENT FOR INJECTABLE SOLUTION is tenecteplase. This information helps identify medicines with the same composition but different brand names.
Who manufactures METALYSE 10,000 UNITS (50 MG) POWDER AND SOLVENT FOR INJECTABLE SOLUTION?
METALYSE 10,000 UNITS (50 MG) POWDER AND SOLVENT FOR INJECTABLE SOLUTION is manufactured by Boehringer Ingelheim International Gmbh. Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of METALYSE 10,000 UNITS (50 MG) POWDER AND SOLVENT FOR INJECTABLE SOLUTION online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether METALYSE 10,000 UNITS (50 MG) POWDER AND SOLVENT FOR INJECTABLE SOLUTION is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to METALYSE 10,000 UNITS (50 MG) POWDER AND SOLVENT FOR INJECTABLE SOLUTION?
Other medicines with the same active substance (tenecteplase) include METALYSE 5,000 UNITS (25 MG) POWDER FOR INJECTABLE SOLUTION, METALYSE 8,000 UNITS (40 MG) POWDER AND SOLVENT FOR INJECTABLE SOLUTION, ACTILYSE powder and solvent for injectable solution and for infusion. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media